XBI
State Street SPDR S&P Biotech ETF
Price Chart
Latest Quote
$128.67
-4.75 (-3.56%)
Current Price
| Previous Close | $133.42 |
| Open | $132.77 |
| Day High | $133.31 |
| Day Low | $128.20 |
| Volume | 8,385,179 |
Fund Information
| Quarterly Dividend / Yield | N/A / 0.32% |
| Net Assets | $8.39B |
| Expense Ratio | 0.35% |
| Category | Health |
| Fund Family | State Street Investment Management |
| Net Asset Value | $133.41 |
| Premium/Discount | -3.55% |
| Quarterly Dividend Yield | 0.32% |
| Exchange | PCX |
📊 ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $132.51 |
| SMA50 | $131.97 |
| SMA200 | $118.78 |
| RSI | 47.15 |
| ATR | 3.7979 |
| Rel Volume | 1.01 |
Performance History
| Week | -5.87% |
| Month | -6.54% |
| Quarter | +3.77% |
| 6 Months | +5.96% |
| YTD | +5.88% |
| Year | +56.58% |
| 3 Years | +54.15% |
| 5 Years | +0.98% |
| 10 Years | +118.73% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $128.67 | 8,405,400 |
| 2026-06-04 | $133.42 | 7,324,200 |
| 2026-06-03 | $129.83 | 8,097,300 |
| 2026-06-02 | $127.76 | 14,202,400 |
| 2026-06-01 | $133.62 | 7,929,300 |
| 2026-05-29 | $136.69 | 6,734,800 |
| 2026-05-28 | $135.99 | 6,861,000 |
| 2026-05-27 | $134.45 | 7,576,700 |
| 2026-05-26 | $133.35 | 5,928,300 |
| 2026-05-22 | $131.66 | 6,467,700 |
| 2026-05-21 | $132.78 | 6,852,700 |
| 2026-05-20 | $131.71 | 10,734,400 |
| 2026-05-19 | $126.79 | 12,027,000 |
| 2026-05-18 | $127.67 | 8,076,600 |
| 2026-05-15 | $130.69 | 9,438,200 |
| 2026-05-14 | $134.85 | 5,197,100 |
| 2026-05-13 | $135.85 | 7,037,200 |
| 2026-05-12 | $134.91 | 5,994,100 |
| 2026-05-11 | $134.75 | 9,991,800 |
| 2026-05-08 | $134.71 | 11,783,800 |
| 2026-05-07 | $133.66 | 10,692,800 |
| 2026-05-06 | $137.68 | 8,468,600 |
About State Street SPDR S&P Biotech ETF
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
📰 Latest News
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech
Motley Fool • 2026-06-05T13:05:31Z
Google, Nvidia Lead Stocks To Watch On This Curated List. See The Full Lineup Here.
Investor's Business Daily • 2026-06-01T20:00:09Z
VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost
Motley Fool • 2026-05-28T12:27:09Z
Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Zacks • 2026-05-27T10:20:03Z
Biotech Investors Are Tuning Out the MAHA Chaos
The Wall Street Journal • 2026-05-20T21:26:00Z
If You Hold This Healthcare ETF, You’re Losing Big
24/7 Wall St. • 2026-05-19T15:12:36Z
Moderna Shares Have Rallied. Why the Stock Could Climb Another 30%.
Barrons.com • 2026-05-11T18:00:00Z
Why This Biotech ETF — The IBD Stock Of The Day — Just Reentered Its Buy Zone
Investor's Business Daily • 2026-05-04T20:18:08Z
Locking In A Quick Gain In This Biotech ETF Made Room For Better Swing Trades; Here's Why
Investor's Business Daily • 2026-05-01T19:08:26Z
Gilead Sciences Crosses Critical Breakout Level. The Stock Can Gain 35% From Here.
Barrons.com • 2026-04-28T15:21:00Z
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.